Nutriband Inc.
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. The company has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. Nutriband Inc. was incorporated in 2016 and is headquartered in Orlando, Florida.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.10 | $433,399 | -$563,104 |
| 2026 Q4 | -0.08 | $400,709 | -$731,830 |
| 2025 Q3 | -0.32 | $346,058 | -$2M |
| 2025 Q2 | -2.12 | $622,452 | -$1M |
| 2025 Q1 | -0.12 | $667,432 | -$1M |
| 2025 Q4 | -0.51 | $642,379 | -$1M |
| 2024 Q3 | -0.12 | $645,796 | -$1M |
| 2024 Q2 | -0.15 | $442,830 |
| -$2M |